top of page
  • Writer's pictureTed Ohashi

Khiron (TSXV: KHRN) introduces cosmeceutical line in Italy

Khiron Life Sciences (TSXV: KHRN) continues to expand its global presence as their Kuida® CBD cosmeceutical line is introduced at Cosmoprof Worldwide Bologna in Italy. This will provide exposure for Kuida® to some 200,000 global retail buyers and is the largest and most important event in the beauty buyers’ yearly calendar. With this step, KHRN increases its footprint in the US $131 billion global skincare market.

As regular readers know, a key component in my assessment of an investment opportunity is management. Often my comments refer to Alvaro Torres, co-founder, Chief Executive Officer and Director and Chris Naprawa, President. But this is an opportunity to feature other important members of the management group.

  • Juan Diego Alvarez, V.P. Regulatory: played an important role by being the first to be able to work his way through the regulatory network in Colombia to get the CBD based Kuida® approved ahead of any competitor. J.D. is acknowledged as the regulatory leader in the region and he proved it once again in this case.

  • Andres Galofre, co-founder, V.P. Business Developments: has 15 years of experience in pharmaceutical marketing, brand management and distribution of prescription drugs and consumer products in Latin America. For example, he was integral in leading the launch of Advil in Colombia which reached a 28% market share. Andres has overall responsibility for the Kuida® line and I am confident he will be successful.

  • Elsa Navarro, Skin Unit Director: says "CBD-based products are rapidly taking centre stage on the global skincare market. With our proven product development and marketing experience it is important for Kuida® to participate in the industry discussion on product innovation, consumer education, legislation, distribution and marketing, in order to assist retail buyers in making informed buying decisions."

For Khiron Life Sciences, management is a very important asset.

206 views0 comments
bottom of page